



We want to save patients with severe cancer and autoimmune diseases
Clinical investigations with our lead antibody CAN04 to our proprietary target


Göran Forsberg, CEO

Safe Harbour Statement

The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia's current thinking with respect to future events and financial performance. Prospective statements only express the assessments and assumptions the company makes at the time of the presentation. These statements are well-considered, but the audience should note that, as with all prospective assessments, they are associated with risks and uncertainties.

Cantargia – opportunity to save lives and create value


- Potentially more effective treatment against novel target in clinically validated pathway
- Right team and clear plan to position our projects and maximize value
- First in class platform technology against novel target



Validating study – counteracting tumor inflammation

CANTOS trial (n=10061)

- Canakinumab (Novartis)
- Reduced lung cancer incidence by 67 % and death by 77 %.



- Clinical validation of IL-1 pathway
- Dose/response
- Cantargia's CAN04 has broader MOA

Canakinumab phase 3 trials (compl 20121/2022)

Adjuvant NSCLC (CANOPY-A) 1500 patients
After surgery, no mets, placebo control

First line (CANOPY-1) 627 patients
Untreated locally advanced/metastatic
Combination Pembro/Platinum doublet



Second line metastatic (CANOPY-2) 240 patients
Previously treated loc adv/metastatic
Combination Docetaxel

...and additional trials in:

- Renal cell cancer
- Gastroesophageal cancer
- Colorectal cancer
- NSCLC

Source clinicaltrials.gov

CAN04 (nidanilimab) added value vs canakinumab




Canakinumab

- Antibody directed against one of the two IL-1 ligands, IL-1β

CAN04:

Double mechanism

- Binds the signaling receptor and counteracts both ligands
- Induce killing via the immune system (ADCC)




..Cantargia has patents on IL1RAP

CAN04 has a strong potential to treat cancer

CAN04 – CANFOUR clinical trial

Phase I/IIa trial - NSCLC and pancreatic cancer

- Phase I data presented orally at ASCO 2019
- 22 patients (NSCLC, pancreatic cancer, colon cancer)
 - Good safety up to 10 mg/kg
 - Significant effect on relevant biomarkers (IL-6, CRP)
 - 9 pts had stable disease up to 6 months
- Phase IIa: (appr 20 centres)
 - FPI Jan 2019 –Data early 2020
 - Combination with standard therapy (appr 30 pat per arm) -safety and efficacy
 - NSCLC Cisplatin/Gemcitabine
 - Pancreatic cancer Gemcitabine/nab-paclitaxel
 - Monotherapy (20 pat) fully recruited, 15 mg/kg to start – safety and biomarkers
- ..and new complementary trial to open in USA



Details on www.clinicaltrials.gov

Generation of data instrumental for next phase of development

Chemoresistance

IL-1 β induced methylation of the estrogen receptor ER α gene correlates with EMT and chemoresistance in breast cancer cells

[CANCER RESEARCH 62, 910–916, February 1, 2002]

Autocrine Production of Interleukin 1 β Confers Constitutive Nuclear Factor Activity and Chemoresistance in Pancreatic Carcinoma Cell Lines¹

Alexander Arlt,² Jens Vorndamm,² Susanne Mürköster, Honggang Yu, Wolfgang E. Schmidt, Ulrich R. Fölsch, and Heiner Schäfer³

IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel

Zhen Ning Wee¹, Siti Maryam J.M. Yatim¹, Vera K. Kohlbauer¹, Min Feng¹, Jian Yuan Goh¹, Bao Yi¹, Puay Leng Lee¹, Songjing Zhang¹, Pan Pan Wang^{2,3}, Elgene Lim⁴, Wai Leong Tam^{1,5}, Yu Cai^{3,6}, Henrik J. Ditzel^{7,8}, Dave S.B. Hoon⁹, Ern Yu Tan¹⁰ & Qiang Yu^{1,3,11,12}

Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma

Daoxiang Zhang¹, Lin Li¹, Hongmei Jiang¹, Brett L. Knolhoff¹, Albert C. Lockhart¹, Andrea Wang-Gillam¹, David G. DeNardo¹, Marianna B. Ruzinova², and Kian-Huat Lim

Serum levels of IL-6 and IL-1 β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer

S Mitsunaga^{*,1,2}, M Ikeda¹, S Shimizu¹, I Ohno¹, J Furuse³, M Inagaki⁴, S Higashi⁵, H Kato⁵, K Terao⁶ and A Ochiai²

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth


Mélanie Bruchard^{1,2,8}, Grégoire Mignot^{1,2,8}, Valentin Derangère^{1,2}, Fanny Chalmin^{1,2}, Angélique Chevriaux¹⁻³, Frédérique Végran^{1,2}, Wilfrid Boireau⁴, Benoit Simon⁴, Bernhard Ryffel⁵, Jean Louis Connat⁶, Jean Kanellopoulos⁷, François Martin^{1,2}, Cédric Rébé¹⁻³, Lionel Apetoh^{1-3,8} & François Ghiringhelli^{1-3,8}

Tumor-Stroma IL1 β -IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer

Daoxiang Zhang¹, Lin Li¹, Hongmei Jiang¹, Qiong Li^{1,2}, Andrea Wang-Gillam¹, Jinsheng Richard Head³, Jingxia Liu⁴, Marianna B. Ruzinova⁵, and Kian-Huat Lim¹

Resistance against several chemotherapies mediated by IL-1

Targeting IL1RAP allows synergistic effects with Cisplatin/Gemcitabine



- CAN04 increases antitumor effects of platinum compounds (cisplatin, carboplatin, oxaliplatin)
- CAN04 counteracts toxicity from platinum compounds

10 mice per group
NSCLC PDX

Synergy with chemotherapy in line with current development strategy

Upcoming US phase I clinical trial

PreIND meeting held, IND submission Jan 2020

Combination with checkpoint inhibitor in patients that have relapsed PD1/PDL-1 therapy


Primary endpoint safety, secondary endpoints include biomarkers and efficacy

Indications include NSCLC, HNSCC and bladder cancer (18 patients)

Strong US centres, Coord investigator Prof Roger Cohen, UPenn

IL1RAP platform to treat serious diseases

- Three different systems signal through IL1RAP
- These systems contribute to various inflammatory diseases
- Can be blocked by Cantargia's antibodies against IL1RAP



Cantargia partnership with Panorama Res Inc (Sunnyvale, CA)
Selection of clinical candidate 2019

Significant value inflection points ahead of CANFOUR results

2019

- Clinical progress and initial phase IIa results
- Phase IIa monotherapy results (biopsies, biomarkers)
- Preclinical progress (immuno-oncology effects, combinations etc)
- CANxx progress

2020

- US clinical trial, IND submission and start
- Phase IIa combination results
- Phase IIa expansion

Significant data to secure newsflow 2019-2020

Cantargia

- Specialized in antibody therapy/immunology/oncology
- Lead antibody CAN04 (nidanilimab) in phase IIa clinical development, pathway clinically validated, data early 2020
- Platform around IL1RAP, lead candidate for autoimmunity and inflammatory disease 2019
- Granted IP - therapeutic target IL1RAP and CAN04
- Strong management team with proven track record in clinical development and business development
- Listed on Nasdaq Stockholm
- More than 5000 shareholders incl strong long term investors
- Based in Lund, Sweden

Financial highlights

- Share price: 15.20 SEK (1.56 USD), Nov 15, 2019
- Market cap: 1107 MSEK (113 MUSD), Nov 15, 2019
- Cash: 195 MSEK (20.2 MUSD), Sep 30, 2019

Current owners (Sep 30, 2019)

Sunstone	7.5%
4th AP fund	6.6%
Alecta	6.6%
1st AP fund	6.3%
Avanza Pension	5.8%
Öhman Bank S.A.	4.3%
SEB S.A.	3.5%
2nd AP fund	3.0%
Mats Invest AB	1.8%
Kudu AB	1.7%
Others	53.2%